...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Biochemical Genetics >The Association of Plasminogen Activator Inhibitor Type 1 (PAI-1) Level and PAI-1 4G/5G Gene Polymorphism with the Formation and the Grade of Endometrial Cancer
【24h】

The Association of Plasminogen Activator Inhibitor Type 1 (PAI-1) Level and PAI-1 4G/5G Gene Polymorphism with the Formation and the Grade of Endometrial Cancer

机译：纤溶酶原激活剂抑制剂1（PAI-1）水平和PAI-1 4G / 5G基因多态性与组膜癌等级的关联

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Plasminogen activator inhibitor type 1 (PAI-1) is a serine protease inhibitor (Serpine 1), and it inhibits both tissue plasminogen activator and urokinase plasminogen activator which are important in fibrinolysis. We aimed to find whether there is a possible association between PAI-1 level, PAI-1 4G/5G polymorphism, and endometrial cancer. PAI-1 levels in peripheral blood were determined in 82 patients with endometrial carcinoma and 76 female healthy controls using an enzyme-linked immunoassay (ELISA). Then, the genomic DNA was extracted and screened by reverse hybridization procedure (Strip assay) to detect PAI 1 4G/5G polymorphism. The levels of PAI-1 in the patients were higher statistically in comparison to controls (P < 0.001). The distribution of PAI-1 4G/5G polymorphism was quite different between patients and controls (P = 0.008), and 4G allelic frequency was significantly higher in the patients of endometrial cancer than in controls (P = 0.026). We found significant difference between Grade 1 and Grade 2+3 patients in terms of the PAI-1 levels (P = 0.047). There was no association between PAI-1 4G/5G polymorphism and the grades of endometrial cancer (P = 0.993). Our data suggest that the level of PAI-1 and PAI-1 4G/5G gene polymorphism are effective in the formation of endometrial cancer. PAI-1 levels are also associated with the grades of endometrial cancer.
机译：纤溶酶原激活物抑制剂型1（PAI-1）是丝氨酸蛋白酶抑制剂（蛇胺1），并且抑制纤维蛋白溶解中重要的组织纤溶酶原激活剂和尿激酶纤溶酶原激活剂。我们旨在找到PAI-1水平，PAI-1 4G / 5G多态性和子宫内膜癌之间的可能关联。在82例子宫内膜癌和76例女性健康对照中使用酶联免疫测定（ELISA）确定外周血中的PAI-1水平。然后，通过逆转录程序（条形测定）来提取和筛选基因组DNA，以检测PAI 1 4G / 5g多态性。与对照组相比，患者中PAI-1的水平更高（P <0.001）。 PAI-1 4G / 5G多态性的分布在患者和对照之间存在差异（p = 0.008），子宫内膜癌患者的4g等位基因频率显着高于对照组（p = 0.026）。我们在PAI-1水平方面发现1年级和2级+ 3名患者之间的显着差异（P = 0.047）。 PAI-1 4G / 5G多态性与子宫内膜癌等级之间没有关联（P = 0.993）。我们的数据表明，PAI-1和PAI-1 4G / 5G基因多态性的水平在组膜癌的形成方面是有效的。 PAI-1水平也与子宫内膜癌等级相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号